Exscientia (EXAI) Stock Analysis

What Exscientia does

Exscientia plc is a pioneering pharmatech firm that leverages artificial intelligence (AI) to revolutionize drug discovery and development. The company provides a comprehensive, AI-driven platform that spans the entire drug development lifecycle. This integrated system supports crucial stages, including identifying disease targets, designing potential drug candidates, developing translational models, and optimizing patient selection for clinical trials. A key area of focus for Exscientia is the development of small molecule drug candidates. Through its advanced AI capabilities, the platform not only facilitates the efficient design of novel drug molecules but also employs AI-guided assessments to ensure patients receive the most suitable therapeutic interventions. Established in 2012, Exscientia plc is headquartered in Oxford, United Kingdom.

Key metrics

ETFs linked to EXAI

Broad-market and Healthcare sector ETFs an investor holding Exscientia is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how EXAI fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Exscientia?

Exscientia trades under the ticker EXAI on NASDAQ.

Which exchange is EXAI listed on?

EXAI is listed on NASDAQ.

What sector does Exscientia operate in?

Exscientia is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze EXAI in a portfolio?

PortView shows EXAI's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.